Latest news with #KhaledMusallam
Al Etihad
14-05-2025
- Health
- Al Etihad
New Thalassemia and Sickle Cell Centre opened at Burjeel Medical City in Abu Dhabi
14 May 2025 22:26 ABU DHABI (ALETIHAD)Burjeel Holdings has launched a Thalassemia and Sickle Cell Centre at Burjeel Medical City (BMC) in Abu Dhabi, marking a significant step towards redefining the standard of care for individuals with inherited blood launch took place under the patronage and in the presence of Sheikha Shaikha bint Saif bin Mohamed Al Nahyan, wife of Sheikh Dr. Sultan bin Khalifa Al Nahyan, Advisor to His Highness the President and Chairperson of the Emirates Thalassemia her opening speech on the occasion, Sheikha Shamma said, "In my mother's unwavering commitment to thalassemia patients, I have witnessed how compassion, when paired with vision and persistence, can transform countless lives across generations and beyond borders."The newly inaugurated Thalassemia and Sickle Cell Centre by Burjeel Holdings' state-of-the-art facility will provide compassionate and comprehensive care to patients and their families," she centre was inaugurated in a grand ceremony also attended by Sheikh Khalifa bin Sultan bin Khalifa Al Nahyan, Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Omran Al Khoori, Board Member, and a number of Burjeel opening was also attended by members of the Board of Directors of the Emirates Thalassemia Society, and a number of leaders from the Department of Health in Abu centre supports individuals living with thalassemia and sickle cell disease by delivering a holistic, patient-centric, and evidence-based model of care, supported by a multidisciplinary team of world-renowned experts. The centre offers fully integrated outpatient services and a dedicated transfusion unit operating seven days a week. The centre is distinguished by several key differentiators, including extended transfusion services across the UAE via Burjeel's hospital network, internationally validated MRI quantification of iron overload in the heart and liver, and in-house molecular genotyping capabilities. Prof. Khaled Musallam, Group Chief Research Officer of Burjeel Holdings and Director of the Thalassemia and Sickle Cell Centre, said, "What makes this centre unique is the combination of global clinical expertise, access to the latest therapies, and the ability to deliver care in line with international guidelines authored by the very people leading the services here."With an international advisory board of global key opinion leaders, the centre adheres to leading global standards, including those of the Thalassaemia International Federation, with necessary local adaptations to meet patients' centre will also work closely with the Centre for Research on Rare Blood Disorders (CR-RBD) at BMC, also headed by Prof. Khaled Musallam, to identify and enroll eligible patients in global clinical trials, ensuring access to the latest innovations in treatment, including disease-modifying and curative has swiftly become recognised as one of the most active hubs for research on haheemoglobin disorders globally. Source: Aletihad - Abu Dhabi
Al Etihad
17-04-2025
- Health
- Al Etihad
MENA Congress for Rare Diseases 2025 opens in Abu Dhabi
17 Apr 2025 17:08 ABU DHABI (ALETIHAD)The MENA Congress for Rare Diseases 2025, the region's largest and most comprehensive event of its kind, officially opened in Abu Dhabi on in partnership with Burjeel Medical City, the four-day congress brings 160 speakers, including 55 international experts from 24 countries, to address the latest advancements in rare disease diagnosis, treatment, and over 1,500 attendees, including 30 percent from outside the UAE representing more than 50 countries, the event serves as a vital global platform for collaboration and Ayman El-Hattab, Congress President and Director of the Genetics and Rare Disease Centre at Burjeel Medical City, said, 'This congress is a unique platform that brings all stakeholders involved in rare diseases to one place to obtain the most updated knowledge, exchange experiences, advance research, and explore new collaborations. Our aim is to ultimately improve the care and quality of life for individuals living with rare diseases in the region and beyond.'Highlighting the scientific rigour of the event, Prof. Khaled Musallam, Head of the Scientific Committee and Group Chief Research Officer at Burjeel Holdings, stated, 'The MENA region bears a higher burden of rare diseases, and this congress reflects our collective commitment to addressing the gaps in care, diagnostics, and treatment. Through science, innovation, and collaboration, we are shaping a better future for patients affected by rare diseases.'A key highlight of this year's congress is the spotlight on Burjeel Medical City's new Genetics and Rare Disease Centre, which provides comprehensive, evidence-based care for individuals with rare and genetic conditions. The Award for Outstanding Achievements in Rare Diseases was presented during the opening ceremony to Alexandra Heumber Perry, CEO of Rare Diseases International; Svein Olaf Olsen, Founder and Owner of Anzyz Technologies AS; Dr. Khawla Alshehhi, Ph.D (Special and Inclusive) from The British University in Dubai; Prof. Brahim Tabarki Melaiki, Consultant Pediatric Neurology, Prince Sultan Military Medical City, Saudi Arabia; Dr. Mohamed Alameri, Section Head – Studies and Special Projects, DOH – Abi Dhabi; and Dr. David Kasper, CEO ARCHIMEDlife GmbH, Austria.
